Whereas, to our knowledge, the roles of AC084082.3 and C22orf34 in tumors have not been reported in the literature to date, several studies indicate that the preselected candidate LINC00662, which showed a genotype-based expression in serum associated with GBC risk, might be a promising biomarker for cancer diagnosis and therapy. The gene discussed is MIR3667HG; the disease is cancer.